Bright Minds Biosciences Q2 2026 Financial Results and $243M Public Offering Summary

Bright Minds Biosciences Inc. reported its financial results for the second quarter and six months ended March 31, 2026. As of March 31, 2026, the company held cash and cash equivalents of $309.7 million, a significant increase from $82.9 million at the end of September 2025. This boost was primarily driven by a public offering in January 2026, which generated gross proceeds of $243.2 million, and sales under its at-the-market (ATM) program. Research and development expenses for the six-month period surged to $18.7 million, compared to $3.6 million in the prior-year period, largely due to increased novel drug development activities. The company reported a net loss of $18.0 million for the six months ended March 31, 2026, compared to a $2.9 million loss in the same period of 2025. Despite the net loss, the company's working capital improved to $308.5 million. The filing also noted ongoing litigation with its former Chief Medical Officer regarding service termination and equity vesting.